Breast cancer & non-conventional treatments
Despite advances made in conventional cancer treatment for both early and late-stage breast cancer, such treatments have been known to cause severe side effects without offering a curative guarantee.
Breast cancer facts
-
Breast cancer is the most common of all cancers in women and is the leading cause of death from cancer in European women.
-
~332,000 EU women were diagnosed with breast cancer in 2008.
-
1 in 4 breast cancers occur in women under 50.
-
<5% of all breast cancers occur in women younger than 35.
-
1 of 100,000 men is diagnosed with breast cancer per year.
Breast cancer treatment facts
- Breast cancer survival is improving and has doubled in the last 40 years in Europe.
-
~11,400 people die from breast cancer in the UK each year.
-
~691,000 are living with a breast cancer diagnosis in the UK; predicted to rise to 840,000 in 2020.
-
1 in 4 women find the end of treatment the hardest part of breast cancer.
-
1 in 10 breast cancer survivors say they felt ready to move on after end of treatment and hospital discharge.
-
>50% of breast cancer survivors struggle with anxiety at the end of treatment, 31% struggle with depression.
Filling the gap in breast cancer treatment
CAM for breast cancer treatment is one of our most frequently queried topics. To meet patient needs, we have published a patient guide for breast cancer with the support of luxury lingerie company Van de Velde. A print version is available on demand.
Onze visie op kankerbehandelingen
ONZE BELOFTE
-
We investeren in het meest veelbelovende wetenschappelijk onderzoek om meetbare vooruitgang te maken in de strijd tegen kanker. -
Een beter en een langer leven voor de patiënt is het enige doel dat we nastreven. Financieel rendement is geen thema voor ons. -
We gaan op zoek naar opportuniteiten in kankeronderzoek die zullen leiden tot pragmatische oplossingen voor patiënten in nood. -
We streven naar impact en investeren onze middelen daar waar we de snelste vooruitgang zullen boeken. -
Elke kanker verdient evenveel aandacht, ongeacht de prevalentie of de rendabiliteit.